The synthesis of racemic [2-{(4-Chlorophenyl)(4-iodophenyl)) methoxyethyl]-l-piperidine-3-carboxylic acid, (CIPCA) and its radioiodinated analog [125I]CIPCA is described. CIPCA was synthesized from 4-iodobenzoyl chloride in five steps in 16% overall yield. Ammonium sulfate catalyzed solid-state isotopic exchange of CIPCA with Na125I provided [1251]CIPCA in 34% isolated radiochemical yield at a specific activity of 118 Ci/mmol. [125I]CIPCA demonstrated moderate brain extraction and good in vivo radiostability in preliminary biodistribution studies conducted in CD-1 mice.
INTRODUCTION
The neutral amino acid, 7-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central nervous system (1,2), Dysfunctions of the GABA neuronal system have been implicated in the development of neurological disorders such as Huntington's chorea (3), Parkinson's disease (4) and epilepsy (5). In particular, reduced synaptic concentrations of GABA are reported to be a contributory factor in certain seizure disorders in humans (6). Consequently, attention has been directed towards the development of GABA uptake inhibitors as an approach to increase synaptic concentrations of GABA (7). Structure-activity-relationship studies on conformationally restricted GABA analogs demonstrate that the R stereoisomer of nipecotic acid, (R-(-)3-piperidinecarboxylic acid) is an inhibitor of GABA uptake (IC50 = 1.7 pM) with no detectable affinity for GABA receptors (8). The hydrophilic nature of nipecotic acid prevents significant permeation of the blood-brain-barrier following peripheral administration. However, enhancement of brain permeability has been achieved by the introduction of lipophilic groups such as a diphenylmethoxyethyl or a diphenylbutenyl group at the nitrogen atom of nipecotic acid (9). These derivatives often display similar selectivity and, in some instances, increased inhibitor potency for the GABA uptake site (9). Two notable examples are the R stereoisomers of the bis(3-methyl-2-thienyl) analog, (NO 328) and bis(4-chlorophenyl) analog, 1 ( The development of selective, high affinity radioligands for specific neurotransmitter binding sites has played a major role in the rapid growth of neuropharmacology. However, few radioligands are currently available for study of the GABA neuronal system, and development of new ligands in this area has been limited mostly to the benzodiazepine subset of the GABA-benzodiazepine receptor complex. The synthesis of a 18F-labeled GABA uptake inhibitor has been recently reported for positron emission tomography (PET) studies (12). Currently, 3H-labeled (R,S)-nipecotic acid (Kd = 0.62 PM) is the only available radioligand for study of GABA uptake sites (13). This tracer has been used to map GABA uptake sites in rat brain as well as in postmortem brain tissues of normal and Alzheimers disease subjects (14, 15) . A radioiodinated ligand would offer many advantages over a tritium labeled ligand, including a higher specific activity and, therefore, a higher sensitivity for labeling very low receptor densities. An added advantage would be the possibility of conducting in vivo imaging studies with the corresponding 1231-labeled analog using single photon emission computed tomography (SPECT). The objective of this study was to develop an 1251 radioiodinated analog of the prototype GABA uptake inhibitor 1, and to conduct preliminary in vivo biodistribution studies to ascertain its suitability for study of the GABA uptake system. R configuration at the C-3 carbon of the piperidine ring), in conjunction with pharmacological blocking studies, should provide insight into the specificity of the -in a binding of this radiotracer in mouse brain.
RESULTS AND DISCUSSION
In conclusion, we report here the synthesis of an 125I-labeled radiotracer for GABA uptake sites which crosses the blood-brain-barrier and has good in vitra and vivQ stability. The moderately high specific activity (118 Ci/mmol) of [125I]CIPCA is adequate for in vivo studies in small animals. However, for clinical application a no-carrier-added synthesis of the corresponding 123I-labeled analog is preferable in order to minimize possible pharmacological or toxicity effects (11).
[123I]CIPCA is a potentially useful radiotracer for scintigraphic visualization of GABA uptake sites in brain by single photon emission computed tomography (SPECT).
EXPERIMENTAL
Melting points were obtained with a Thomas-Hoover melting point apparatus Infrared spectra were recorded on a Perkin-Elmer 727B 1H-NMR spectra were obtained on a and are uncorrected. The radiochemical purity of [125I]CIPCA was determined using a pBondapak Cyano column, 10 p, (3.9 x 300 mm) in series with a Cyano guard cartridge (Brownlee) with 0.1 M ammonium acetate (pH=6.8):CH3CN (7:3, v/v) as the mobile phase at a flow rate of 1.5 mL/min. UV absorbance was monitored at 214 nm. The retention time for [1251]CIPCA under these conditions was 8.7 min. Specific activity was determined from a standard curve relating mass to UV absorbance peak area (19).
4-Chloro-4'-iodobenzophenone (a
Aluminum chloride (2.25 g, 16.9 mmol) was added in one portion to a suspension of 4-iodobenzoyl chloride (2.25 g, 8.4 mmol) in dry chlorobenzene (15 mL) at room temperature under an argon atmosphere. The pale yellow solution was then heated at 70 OC (oil-bath) for 3 h and the warm reaction mixture poured over a mixture of crushed ice and concentrated HCl (10 mL). The aqueous suspension was extracted with CHC13 (3 x 50 mL) and the combined organic layers washed successively with aqueous 10% Na2C03 (50 mL), H 2 0 (50 mL) and dried (Na2S04 The reaction mixture was poured into saturated aqueous K2CO3 (100 mL), extracted with Et20 (2 x 100 mL) and dried (MgS04 
4-Chloro-4'-iodobenzhydrol

4-Chloro-4'-iodobenzhydryl chloride (4)
A solution of 3 (2.0 g, 5.8 mmol) in dry CHC13 (20 mL) was treated in one portion under argon with excess SOC12 (20 mL) and refluxed for 18 h. Following removal of volatiles under reduced pressure the residue was partitioned between CHC13 (100 mL) and H 2 0 (50 mL). The aqueous layer was further extracted with CHC13 (100 mL), and the combined organic layers dried (Na2S04), filtered, and evaporated under reduced pressure. Flash chromatography of the crude product were combined in a 5 mL Pierce Reacti-vial, the vial sealed with a teflon-lined cap and heated in an oil bath at 160-170 O C for 45 min. The warm reaction mixture was solubilized in hot THF (5 mL) and poured into a mixture of 100 mL of ether:
saturated brine (1:l). The organic layer was removed, the aqueous layer further extracted with ether (2 x 50 mL), and the combined organic layers dried (Na2S04).
Removal of solvent under reduced pressure and flash chromatography CHC13:CH30H (197: 3)] of the residue afforded 0.80 g (55%) of a pale yellow oil. [2-( (4-Chlorophenyl)(4-iodophenyl~)methoxyethyll-l-piperidine-3-carboxylic acid (2) A mixture of 6 (0.15 g, 0.3 mmol) and a 1.0 M solution of aqueous LiOH (0.5 mL, 0.5 mmol) in C H 3 0 H (5 mL) was refluxed with stirring at 65 OC until system, and the radiochemical purity of the product was 60%. Further purification was achieved by chromatography on a cyano Sep Pak (Waters). The crude product (7.1 mCi) in EtOH (0.50 mL) was diluted with H 2 0 (10 mL) and transferred to an activated cyano Sep Pak [prewashed with CH30H (5 mL) followed by H 2 0 (5 mL)].
The Sep Pak was rinsed sequentially with 0.01% aqueous NaI (5 mL) and H 2 0 (5 mL)
to remove residual Na125I. Following sequential rinsing of the Sep Pak with CH30H:H20 (1:9, v/v; 5 mL) and CH30H:H20 (1:4, v/v; 5 mL), elution with 100% CH30H (2 x 1 mL) afforded 2.65 mCi of [125I]CIPCA with a radiochemical purity of 95%. Isolated radiochemical yield was 34% and the specific activity was determined to be 118 Ci/mmol. The solvent was removed using an argon stream, the product redissolved in absolute EtOH to a concentration of 1 mCi/mL and stored at 4 OC until
